Hood River Capital Management LLC Trims Stock Holdings in Lantheus Holdings, Inc. $LNTH

Hood River Capital Management LLC lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 45.0% during the second quarter, Holdings Channel reports. The fund owned 407,177 shares of the medical equipment provider’s stock after selling 332,976 shares during the quarter. Hood River Capital Management LLC’s holdings in Lantheus were worth $33,332,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LNTH. PNC Financial Services Group Inc. grew its holdings in shares of Lantheus by 55.0% during the first quarter. PNC Financial Services Group Inc. now owns 11,813 shares of the medical equipment provider’s stock worth $1,153,000 after buying an additional 4,191 shares in the last quarter. Townsquare Capital LLC lifted its stake in shares of Lantheus by 24.7% during the 1st quarter. Townsquare Capital LLC now owns 15,449 shares of the medical equipment provider’s stock worth $1,508,000 after purchasing an additional 3,063 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Lantheus by 2,286.7% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 63,104 shares of the medical equipment provider’s stock worth $6,159,000 after purchasing an additional 60,460 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Lantheus in the first quarter valued at $55,941,000. Finally, Eagle Global Advisors LLC acquired a new position in Lantheus in the first quarter valued at $9,290,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Lantheus stock opened at $63.30 on Monday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $4.20 billion, a P/E ratio of 26.60 and a beta of -0.10. The firm has a fifty day moving average of $55.50 and a 200-day moving average of $63.43. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $111.29.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

LNTH has been the subject of a number of recent analyst reports. Truist Financial restated a “hold” rating and issued a $61.00 target price (down from $63.00) on shares of Lantheus in a report on Monday, November 10th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. B. Riley dropped their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Weiss Ratings lowered Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Finally, TD Cowen reduced their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, September 15th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $74.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.